Oral citicoline treatment improves visual pathway function in glaucoma

Med Sci Monit. 2003 Mar;9(3):PI24-8.

Abstract

Background: Increased latency and reduced amplitude of visual evoked potentials (VEP), frequently encountered in ocular hypertension or open-angle glaucoma, suggest slowed neural conduction in the visual pathways. An improvement in VEP latency and amplitude has been reported following repeated intramuscular injections of citicoline, a neuroprotective drug. Our aim was to find whether citicoline given orally would produce a similar effect.

Material/methods: VEP latency and amplitude were measured in 21 glaucomatous eyes prior to and after two bi-weekly courses of citicoline taken orally in a dose of 1 gram/day. The treatment courses were separated by a two-week break; post-treatment VEP measurement was performed two weeks after the end of the second treatment.

Results: 62% of the eyes showed a response to the treatment, with VEP latency reduced from 123.5 (3.9 SEM) ms to 111.9 (1.9 SEM) ms (P=0.0008), and VEP amplitude increased from 6.56 (1.39 SEM) to 7.88 (1.16 SEM) (P=0.04).

Conclusions: Citicoline given orally improves visual evoked potentials in some glaucoma patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aged
  • Cytidine Diphosphate Choline / administration & dosage*
  • Evoked Potentials, Visual / drug effects
  • Female
  • Glaucoma / drug therapy*
  • Glaucoma / physiopathology*
  • Humans
  • Male
  • Middle Aged
  • Nerve Degeneration / drug therapy
  • Nerve Degeneration / physiopathology
  • Neuroprotective Agents / administration & dosage
  • Visual Pathways / drug effects*
  • Visual Pathways / physiopathology

Substances

  • Neuroprotective Agents
  • Cytidine Diphosphate Choline